On Monday, Beam Therapeutics Inc (NASDAQ: BEAM) was 3.05% up from the session before settling in for the closing price of $23.30. A 52-week range for BEAM has been $20.84 – $35.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 43280.87% over the past five years. When this article was written, the company’s average yearly earnings per share was at -4.88%. With a float of $88.04 million, this company’s outstanding shares have now reached $99.84 million.
Let’s look at the performance matrix of the company that is accounted for 483 employees. In terms of profitability, gross margin is 74.05%, operating margin of -654.25%, and the pretax margin is -593.06%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 11.82%, while institutional ownership is 69.86%. The most recent insider transaction that took place on Feb 18 ’25, was worth 220,045. In this transaction SVP, Finance and Treasurer of this company sold 6,287 shares at a rate of $35.00, taking the stock ownership to the 37,527 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Legal Officer sold 10,000 for $34.00, making the entire transaction worth $340,000. This insider now owns 102,968 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.73% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.58, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.84 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc (NASDAQ: BEAM) saw its 5-day average volume 1.89 million, a positive change from its year-to-date volume of 1.63 million. As of the previous 9 days, the stock’s Stochastic %D was 17.96%. Additionally, its Average True Range was 2.12.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 18.49%, which indicates a significant decrease from 27.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.02% in the past 14 days, which was higher than the 75.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.65, while its 200-day Moving Average is $25.81. Nevertheless, the first resistance level for the watch stands at $24.49 in the near term. At $24.98, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.42. If the price goes on to break the first support level at $23.56, it is likely to go to the next support level at $23.12. The third support level lies at $22.63 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are 99,785K outstanding shares of the company, which has a market capitalization of 2.40 billion. As of now, sales total 63,520 K while income totals -376,740 K. Its latest quarter income was 30,070 K while its last quarter net income were -90,350 K.
